Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In acromegaly, nearly 40% of patients fail to control GH/IGF-I levels with somatostatin analogues (SA). Dopaminergic agonists (DA) are even less effective, but combination therapy with SA and DA normalizes IGF-I levels in 33-56% of patients in short-term studies. This study was designed to evaluate short and long term efficacy of cabergoline in controlling IGF-I levels in acromegalic patients receiving octreotide.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federal University of São Paulo
• Treatments: Cabergoline; Octreotide

Criteria

Inclusion Criteria:

• Active disease, under octreotide treatment at least 9 months

Exclusion Criteria:

• Cabergoline allergy